Pediatrics

Phase II Pro 542 Trial Begins in HIV Infected Children

Published in AIDS Weekly, December 18th, 2000

Progenics Pharmaceuticals, Inc. (PGNX), Tarrytown, New York, announced that treatment of HIV positive pediatric patients had begun in a Phase II study of PRO 542, the company's most clinically advanced HIV inhibitor.

The company also announced the publication of a scientific article describing the results of a previous Phase I/II clinical trial of PRO 542 in HIV infected children, including those resistant to available antiviral therapies. The article appeared in the December 2000 issue of The Journal of Infectious Diseases (vol. 182, no. 6).

The goal of the initiated Phase II trial is to define the dose and frequency of administration of PRO...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-12-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry